Submit to Special Issue Submit Abstract to Special Issue Review for JPM Propose a Special Issue

Journal Menu

Journal Browser

Special Issue "Personalized Medicine in Otolaryngology and Head and Neck Surgery"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 5 December 2023 | Viewed by 2020

Share This Special Issue

Special Issue Editors

Prof. Dr. Jerome Rene Lechien
E-Mail Website
Guest Editor

1. Division of Laryngology and Bronchoesophagology, Department of Otolaryngology-Head & Neck surgery, EpiCURA Hospital, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons, Mons, Belgium
2. Department of Otolaryngology-Head & Neck surgery, Foch Hospital, Paris Saclay University, Paris, France
Interests: laryngology; otolaryngology; head neck; surgery; robotic; laryngeal; larynx

Prof. Dr. Carlos M. Chiesa-Estomba

E-Mail Website
Guest Editor

1. Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain
2. Department of Otorhinolaryngology-Head and Neck Surgery, Policlinica Guipuzcoa, San Sebastian, Spain
3. Biodonostia Research Institute, San Sebastian, Spain
4. Faculty of Medicine, Deusto University, San Sebastian, Spain
Interests: head and neck; salivary gland; reconstructive surgery; laryngology; artificial intelligence; 3D bioprinting
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized medicine can predict the risk of underlying diseases through more accurate diagnosis, provide more effective and targeted treatment, and design the best treatment plan for patients, in order to maximize the therapeutic effect and minimize the side effects and even prevent the occurrence of diseases. New and personalized diagnostics and treatment innovations are necessary steps to improve the quality of treatment and quality of life for patients with otolaryngology–head and neck diseases.

This Special Issue is dedicated to personalized medicine in otolaryngology–head and neck surgery. All original research and review articles investigating personalized diagnostic and therapeutic approaches are welcome. Particular attention will be paid to papers that propose future management of patients considering the patients’ features, individualities, and new technologies.

Prof. Dr. Jerome Rene Lechien
Prof. Dr. Carlos M. Chiesa-Estomba
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

personalized
medicine
therapeutic
treatment
diagnosis
surgery
otolaryngology
technology
diagnostic
medication

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy

and

J. Pers. Med. 2023, 13(7), 1129; https://doi.org/10.3390/jpm13071129 - 12 Jul 2023

Viewed by 559

Abstract

Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, is used at many medical facilities. Although TESS has been used for dysphagia in several fields, its safety and efficacy in patients with head and neck cancer remain to be clarified. Therefore, this study evaluated the safety of TESS in ten patients with head and neck cancers undergoing CRT. Swallowing rehabilitation intervention and TESS implementation were performed for all patients during CRT. Non-blood-toxicity adverse events (AEs), such as dermatitis and mucositis, occurred during CRT; however, the severity was less than grade 3. No patient experienced pain due to TESS. As survival time analysis using the Kaplan–Meier method for interferential current device implementation rates revealed a feasibility of 100% for up to 60 Gy and a feasibility of 78% for up to 70 Gy, TESS may be feasible until 70 Gy. This study confirmed the feasibility and safety of TESS in the head and neck region during CRT. Although the precise mechanism of TESS on dysphagia remains unclear, its continued use has great potential for improving sensory disturbance. Full article

(This article belongs to the Special Issue Personalized Medicine in Otolaryngology and Head and Neck Surgery)

► Show Figures

Figure 1

Open AccessFeature PaperArticle

Cost-Effectiveness Study of Double-Flange Voice Prostheses in the Treatment of Periprosthetic Leakage in Laryngectomized Patients

Pedro Rodríguez-Lorenzana

Miguel Mayo-Yáñez

Carlos M. Chiesa-Estomba

and

J. Pers. Med. 2023, 13(7), 1064; https://doi.org/10.3390/jpm13071064 - 29 Jun 2023

Viewed by 474

Abstract

Background: Tracheoesophageal speech with a voice prosthesis is considered the rehabilitation treatment of choice in laryngectomized patients. The main reasons for prosthesis failure are endoprosthetic leakage and periprosthetic leakage. The Provox XtraSeal^® stent incorporates an additional double flange on the esophageal side to prevent periprosthetic leakage. The objective of this study is to compare the duration and costs of the Provox Vega^® and Provox XtraSeal^® prostheses used in these patients in a tertiary university hospital. Materials and methods: A prospective crossover case study of laryngectomees with Provox Vega^® who underwent Provox XtraSeal^® placement due to recurrent periprosthetic leaks and decreased theoretical prosthesis life. The duration and possible factors affecting voice prostheses were studied using Kaplan–Meier curves and Cox regression. A cost-effectiveness analysis was carried out from the perspective of the Spanish National Health System with an incremental cost-effectiveness calculation. Results: A total of 38 patients were recruited, 35 men and 3 women, with a mean age of 66.26 ± 9.36 years old. Information was collected from 551 voice prostheses, 484 Provox Vega^® and 68 Provox XtraSeal^®. The mean duration of Provox Vega^® was 119.75 ± 148.8 days and that of Provox XtraSeal^® was 181.99 ± 166.07 days (p = 0.002). The most frequent reason for replacement was endoprosthetic leakage in both groups: 283 (60.86%) in the case of Provox Vega^® and 29 (48.33%) in that of XtraSeal^® (p < 0.000). To obtain no cost differences (ICE ~ 0) between Provox Vega and Provox XtraSeal, the latter should cost EUR 551.63. Conclusions: The Provox XtraSeal^® is a cost-effective option in patients with increased prosthesis replacements due to periprosthetic leakage, reducing the number of replacements, increasing the duration of the prosthesis, and providing savings compared to Provox Vega^®. Full article

(This article belongs to the Special Issue Personalized Medicine in Otolaryngology and Head and Neck Surgery)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Non-Squamous Cell Carcinoma of the Larynx: A State-of-the-Art Review

Carlos M. Chiesa-Estomba

Maria Rosaria Barillari

and

J. Pers. Med. 2023, 13(7), 1084; https://doi.org/10.3390/jpm13071084 - 30 Jun 2023

Viewed by 673

Abstract

(1) Background: Non-squamous cell laryngeal carcinoma includes endothelial tumors, such as minor salivary gland tumors, lymphoepithelial tumors, neuroendocrine tumors, soft and hard tissue sarcomas, and malignant melanomas. (2) Methods: A state-of-the-art review using the MEDLINE/PUBMED, Google Scholar, Ovid Medline, Embase, and Scopus electronic databases was performed. (3) Conclusions: In order to optimize overall treatment outcomes, a multidisciplinary, patient-centered approach to the management of non-SCC of the larynx must be adopted universally; a national or international registry on non-SCC laryngeal cancer can be useful to improve understanding about the behavior of this kind of tumor. Full article

(This article belongs to the Special Issue Personalized Medicine in Otolaryngology and Head and Neck Surgery)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Personalized Medicine in Otolaryngology and Head and Neck Surgery"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI